Triple positivity (TP) for antiphospholipid antibodies(aPL) may identify aPL carriers with poorer prognosis. The clinical impact of TP in primary antiphospholipid syndrome(PAPS) remains unclear and further clinical evidences are needed to validate TP as a marker of severity. The aim of this study was to evaluate the impact of TP on the clinical course of PAPS with thrombosis(t-PAPS). We performed a retrospective analysis of a cohort of t-PAPS patients, comparing groups of patients with TP and non-TP profiles according to their demographic, clinical and laboratory features. We included 105 patients with t-PAPS, the median follow-up time of 3.7 years. Twenty-two patients(21%) had TP; the demographic distribution, the presence of cardiovascular risk factors and the site of thrombosis were similar between TP and non-TP patients. The frequency of thrombotic events did not differ between TP and non-TP patients during the study period. Pregnancy morbidities were more frequent in women with t-PAPS and TP than in those with non-TP profile (80% vs. 52.8%, P 5 0.05). Patients with t-PAPS and TP presented, at diagnosis, higher dRVVT ratio (median R 5 2.44 vs. 1.57, P < 0.0001), higher aCL titer (median 5 50UI vs. 35 UI, P < 0.0001), lower C3 levels (median 5 1.08 vs. 1.30 mg dL 21 , P 5 0.001), lower C4 levels (median 5 0.22 vs. 0.25 mg dL 21 , P 5 0.05) and higher frequency of positive ANA test (50% vs. 20%, P 5 0.008) than patients with t-PAPS and non-TP. Lower-thannormal levels of C3 was independently associated with TP (OR 5 5.1, P 5 0.02). The presence of TP in patients with t-PAPS was associated with immune derangement, with no effect on the clinical course of the disease.
| I N TR ODU C TI ON
Primary antiphospholipid syndrome (PAPS) is a prothrombotic condition that affects different vascular beds, with no detectable underlying diseases, and is associated with the persistent presence of at least one antiphospholipid antibody (aPL): lupus anticoagulant (LAC), anticardiolipin (aCL) or anti-b2glycoprotein I (ab2GP1). 1 Antiphospholipid antibodies are widely used as diagnostic markers of antiphospholipid syndrome (APS), however the profile of these antibodies may also play a role in the clinical presentation of the disease.
Miyakis et al. suggested that APS should be categorized according to aPL positivity, as type I (more than one positive aPL), type IIa (LAC present alone), type IIb (aCL present alone) and type IIc (ab2GP1present alone). 1 Recently, Pengo et al. suggested that the positivity for the three aPL antibodies, known as triple positivity (TP),was an independent risk factor for thrombosis in aPL asymptomatic carriers. 2 Further studies confirmed that TP was a promising prognostic marker able to identify aPL carriers, and possibly APS patients, with poorer prognosis and worse clinical course. 3, 4 However, APS is a heterogeneous disease and the clinical relevance of the aPL profile, in particular TP, in the clinical course of PAPS
has not yet been confirmed. 5, 6 A recent meta-analysis demonstrated that each aPL (LAC, aCL, and aB2GP1) were independently associated with increased risk of thrombosis in PAPS, particularly LAC was associated with the highest risk. 7 Furthermore, aPL test results are highly variable across different laboratories, [8] [9] [10] and the inter-laboratory variability may impact the use of these tests as prognostic markers.
Thus, we hypothesized that aPL profile may not be an overall prognostic marker of PAPS and should be validated according to local particularities. In this context, the aim of this study was to evaluate the impact of aPL profiles, in particular TP, on the clinical presentation of thrombotic PAPS. In addition, we described the dRVVT results as dRVVT ratio, which is the ratio between screening and confirmatory results.
| M E TH ODS
The antiphospholipid antibodies with solid phase were tested in patient serum by "in house" ELISA immunological assays, with cardiolipin or b2GP1 as antigen (Sigma-Aldrich, USA), as previously described.
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| Statistical analysis
Descriptive statistics were used for categorical data and expressed as frequencies (percentage). Fisher exact test was used to compare categorical data. Continuous data were reported as median and interquartile range (IQR) and the differences were tested using MannWhitney. Correlation analyses were performed using Spearman test.
Univariate logistic regression was used to evaluate the association of serological and clinical parameters with TP. A multivariate logistic regression analysis was performed with the parameters that were statistically associated with TP by univariate analysis, with a P value of 0.1 or less, and adjusted for age and gender. The multivariate logistic regression models were run using block entry. Data were analyzed using SPSS for Windows version 15.0 (SPSS, Chicago, IL). Graphics were generated using GraphPad Prism, version 5 for Windows (GraphPad Software, La Jolla, CA). P < 0.05 was considered statistically significant.
| R ESU L TS
We included a total of 105 patients with thrombotic PAPS with a median follow-up time of 3.7 years (IQR 1.1-8.5 years). Twenty-two and 6.6% double positivity for aCL and ab2GP1.
The demographic distribution was similar between patients with TP and non-TP profile (Table 1) , and the presence of TP was not associated with age or gender. As the presence of cardiovascular risk factors may also worsen the prognosis of APS, we evaluated whether patients had comorbidities associated with higher risk of cardiovascular events, such as hypertension, diabetes, dyslipidemia and smoking. The prevalence of cardiovascular risk factors was similar between patients with TP and non-TP profile (Table 1) .
Patients with TP presented, at diagnosis, higher dRVVT ratio 
| Differences within groups of aPL profile
We also evaluated the occurrence of multiple thrombosis, pregnancy 
| D I SCUSSION
Patients with t-PAPS present potential risk for thrombosis recurrence, even under anticoagulation treatment, 16 and for the development of systemic autoimmune disease. 17 Up to 10% of PAPS patients develop SLE in the course of the disease 18 and thrombosis recurrence rate is about 5 to 16%. 19, 20 However, there are no validated parameters for risk classification in PAPS, and markers of prognosis are needed to improve the treatment approach toward patients with higher risk for developing of PAPS-related complications.
In the present study, we could observe that TP antibody profile in patients with PAPS and thrombosis was associated with a higher frequency of pregnancy morbidities. The site of thrombosis and the occurrence of new thrombotic events were not related to TP profile.
Patients with TP also had evidences of immune derangement, such as higher IgG aCL titers and dRVVT ratio, positive ANA test and complement consumption, the development of systemic autoimmunity however, was rare. When we evaluated each aPL profile separately, we observed that the prognosis of thrombosis was not affected by the presence of LAC. The number of patients in the subgroups, however, was small and no conclusion could be drawn regarding the specific role of LAC in t-PAPS prognosis.
The association of TP with multiple clinical manifestations of PAPS has been documented in a cohort of patients with obstetric PAPS. In that cohort, TP was associated with history of previous thrombosis and higher risk of thrombosis and pregnancy morbidity during new pregnancies. 21 Although our results suggested that TP is associated with the occurrence of both obstetric and vascular complications in PAPS, the risk for obstetric events in women with t-PAPS however, was high in all aPL profiles. That finding raises the necessity of conducting appropriate prophylaxis against these complications in women with PAPS.
We observed no association between TP and the site of thrombosis or thrombosis recurrence. This finding was not expected because previous clinical studies have shown that TP confers higher risk for the development of thrombosis and recurrent thrombotic events. 4, 22, 23 We believe that the risk of thrombosis in APS may not be attributed solely to the aPL profile. It is important to highlight that inter-laboratory variability of aPL assays is high and the results rely on the assays, reagents, equipment and interpretation strategies employed in the laboratories.
The lack of standard assays or reference plasmas contributes to this variability. [8] [9] [10] Therefore, the reproducibility of TP detection between laboratories is expected to be low.
Moreover, clinical parameters may also play a role in the prognosis of PAPS. Recent data from a cohort of patients with APS observed that the aPL profile was not different between patients with or without thrombotic recurrences, while diabetes, familial thrombophilia and anticoagulation withdrawal were independent risk factors for recurrences. 5 Indeed, major risk factors for thrombosis, such as hyperlipidemia, arterial hypertension and obesity, seem to play an important role in thrombosis development and recurrence. [24] [25] [26] [27] A recent APS score of risk, the Global Anti-Phospholipid Syndrome score (GAPSS), demonstrated that hyperlipidemia and hypertension are independent risk factors for poorer outcomes in APS. 24 In the present study, we could observe that cardiovascular risk factors are highly prevalent in our population. Hypertension was present in 32% of patients, 42% had hyperlipidemia and 30% were obese. The prevalence of these comorbidities was similar between patients with or without TP.
In the present study, triple positivity for aPL was also associated with laboratory features that suggest immune derangement, such as higher dRVVT ratio, higher aCL titers, positive ANA and complement C3 consumption. The significance of these findings are yet to be determined, because, although the diagnosis of systemic autoimmunity may be questioned, no patient fulfilled the criteria for SLE or other systemic autoimmunity, and only one patient developed SLE during the follow-up time. In the present study, we observed that C3 levels decrease particularly in patients with TP and remain within the normal range in patients with other aPL profiles. The complement activation in APS was reported in murine models and clinical studies and may contribute to procoagulant activity. 28 In clinical studies, the activation of the complement pathway was detected in all types of aPL profiles, but particularly in patients with LAC, and double or triple positivity of aPL. 29 Hypocomplementemia was also correlated with procoagulant activity in a clinical study that included 36 patients with PAPS. 30 Therefore, complement activation may play a role in the cross-talk between inflammation and hypercoagulability APS. 31 Nevertheless, there are some limitations in this study that must be highlighted. First, this is an observational and retrospective study, and therefore some clinical information may have been missed during the follow-up. Furthermore, t-PAPS is a relatively rare disease, which contributes to the small sample size of the study and may influence the precision of the results. The data associating the presence of TP with concomitant vascular and obstetric complications in PAPS confirms previous data; however the number of pregnant women in the study was low. Prospective studies in women with PAPS would be necessary to evaluate the risk factors associated with the occurrence of both thrombotic and obstetric complications.
In conclusion, our results suggest that classification of aPL profile, in particular triple positivity, was not enough to identify patients at higher risk of severe thrombosis, thrombosis recurrence or other complications of t-PAPS. TP was associated with higher levels of aPL antibodies and complement consumption and the clinical significance of these findings in PAPS is yet to be determined.
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